AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CARL

Bertolini Jeffrey sold $11K of CARL

Bertolini Jeffrey (Chief Operating Officer) sold 747 shares of CARLSMED, INC. (CARL) at $14.39 on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bertolini Jeffrey
Published Oct 6, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CARL
Neutral
high confidence
Mentioned
$CARL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CARLNeutralLow
01

Why it matters

The disclosed sale is small and likely to have limited price impact.

02

Market read

Routine insider transaction with modest size; low trading relevance.

03

What to watch

Potential upcoming corporate events not disclosed may influence future insider activity.

Relevance 2/10Novelty 2/10Timing: today

Background

CARLSMED, INC. (CARL) filed a Form 4 reporting an insider sale by its COO under a 10b5‑1 plan.

Company-level read

Ticker impact

$CARLNeutralHigh confidence
Context

Form 4 shows COO sold 747 shares for $10.7K via 10b5-1 plan, reducing holdings to 22,489 shares.

Expected impact

likely slight pressure as market prices in the small insider sale

Evidence & confidence

The sale amount is modest and disclosed via a pre‑arranged plan, so impact is limited.

Market effects

Sector

None significant for the broader healthcare sector.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be routine and not indicative of any negative outlook.

Key entities

  • Officer
    Bertolini Jeffrey

    Chief Operating Officer of CARLSMED, INC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CARL insider trading history →

Related articles

$CARLHigh

Carlsmed (CARL) Q3 2026 Earnings Call Transcript

Carlsmed (CARL) reported 65% revenue growth in Q3 2026, raising full-year guidance to $78M-$80M. The company launched new products and expects 2027 catalysts. Management updates include new COO, CFO, and Chief Product & AI Officer. Clinical data shows reduced reoperation rates, and new reimbursement codes may boost hospital adoption.

finance.yahoo.com
$CARLMed

Carlsmed Q3 Earnings Call Highlights

Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.

finance.yahoo.com
$CARLHigh

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (

SEC EDGAR 8-K